抗肝癌小分子酪氨酸激酶抑制剂的临床研究进展

doi:10.12092/j.issn.1009-2501.2019.08.017

摘要/Abstract

摘要：

肝癌是严重威胁人类健康的消化系统恶性肿瘤之一。在我国，其发病率位居第四位，死亡率高居第二位。手术治疗有自身局限性，常规化疗药物作用有限，毒副作用大，且没有明显的生存获益。分子靶向治疗能选择性地杀灭肿瘤细胞，对机体的损伤较小，是近年来肿瘤治疗领域新的研究方向。小分子酪氨酸激酶抑制剂（TKIs）作为一类分子靶向药物，已成为当前抗肝癌研究的主流趋势之一。本文主要对已上市和正在进行临床试验的小分子酪氨酸激酶抑制剂抗肝癌最新临床情况作一综述。

关键词: 肝细胞癌, 小分子酪氨酸激酶抑制剂, 临床研究

Abstract:

Liver cancer is one kind of the digestive system cancer which is seriously threatening the health of human. The incidence and mortality of liver cancer rank as the fourth and second in China, respectively. Surgical treatment has its own limitations, and conventional chemotherapy drugs have severe side effects with no obvious survival benefits. In recent years, molecular targeted therapy, which can selectively kill tumor cells and has less damage to the body, has been a new research direction in the field of tumor therapy. Small molecule tyrosine kinase inhibitors (TKIs), a family of molecular targeted drugs, have become one of the mainstreams in anti-hepatocarcinoma research. In this paper we briefly summarize the latest clinical trials of small molecule tyrosine kinase inhibitors, including those both on the market and in clinical trials.

Key words: hepatocellular carcinoma, small molecule tyrosine kinase inhibitors, clinical research

中图分类号:

R735.7

常青青，彭英，王广基，孙建国. 抗肝癌小分子酪氨酸激酶抑制剂的临床研究进展[J]. 中国临床药理学与治疗学, 2019, 24(8): 948-956.

CHANG Qingqing, PENG Ying, WANG Guangji, SUN Jianguo. Clinical research progress of small molecule tyrosine kinase inhibitors as anti-hepatocellular carcinoma agents[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 948-956.

参考文献

［1］李芸, 李兵胜, 张卫芳, 等. miR-146a G＞C基因多态性与中国原发性肝癌患者遗传易感性的Meta分析［J］. 中国临床药理学与治疗学, 2017, 22(7): 779-786.
［2］Keating , Gillian M. Sorafenib: a review in hepatocellular carcinoma［J］. Target Oncol, 2017, 12(2): 243-253.
［3］陆伦根. 原发性肝癌的早期筛查及诊断［J］. 临床肝胆病杂志, 2017, 33(7): 1257-1261.
［4］Dawkins J, Webster RM. The hepatocellular carcinoma market ［J］. Nat Rev Drug Discov, 2019, 18(1): 13-14.
［5］李爱军, 马森林, 吴孟超. 分子靶向药物在肝癌治疗中的作用［J］. 肝胆胰外科杂志, 2015, 27(3): 255-258.
［6］Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial ［J］. J Clin Oncol, 2013, 31(32): 4067- 4075.
［7］Johnson PJ, Qin S, Park JW , et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK- FL study［J］. J Clin Oncol, 2013, 31(28): 3517-3524.
［8］Cainap C, Qin S, Huang WT, et al. Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial ［J］. J Clin Oncol, 2015, 33(2): 172-179.
［9］Cheng AL, Thongprasert S, Lim HY, et al. Randomized, open-label phase 2 study comparing frontline dovitinib vs sorafenib in patients with advanced hepatocellular carcinoma［J］. Hepatology, 2016, 64(3): 774-784.
［10］Zhu AX, Kudo M, Assenat E, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial ［J］. JAMA, 2014, 312: 57-67.
［11］McNamara MG, Le LW, Horgan AM, et al. A phase II trial of second‐line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma ［J］. Cancer, 2015, 121(10): 1620-1627.
［12］Zhu YJ, Zheng B, Wang HY, et al. New knowledge of the mechanisms of sorafenib resistance in liver cancer ［J］. Acta Pharmacol Sin, 2017, 38(5): 614-622.
［13］Schwartz JD. Sorafenib in advanced hepatocellular carcinoma ［J］. N Engl J Med, 2008, 359(23): 378-390.
［14］Cheng A, Kang Y, Chen Z, et al. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma［J］. J Clin Oncol Official J Am Soc Clin Oncol, 2008, 26(15_suppl): 4509.
［15］Pressiani T, Boni C, Rimassa L, et al. Sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (HCC): Safety and efficacy in Child-Pugh (CP) class A and B patients ［J］. J Clin Oncol, 2012, 30(4_suppl): 306.
［16］秦叔逵, 龚新雷. 索拉非尼治疗原发性肝癌的研究进展［J］. 临床肿瘤学杂志, 2008, 13(12): 1057-1068.
［17］Guedes LCR, Cristiane M, Daniel B, et al. Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study ［J］. Invest New Drugs, 2018, 36(5): 911-918.
［18］Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma［J］. Eur J Cancer, 2011, 47(14): 2117-2127.
［19］Ghassan K, Abou A, Donna N, et al. Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802(Alliance) ［J］. J Clin Oncol, 2016, 1: 21-23.
［20］Zhu AX, Rosmorduc O, Evans TRJ, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma ［J］. J Clin Oncol, 2015, 33(6): 559-566.
［21］Trojan J, Waidmann O. Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma ［J］. J Hepatocell Carcinoma, 2016, 3: 31-36.
［22］Rimassa L, Pressiani T, Personeni N, et al. Regorafenib for the treatment of unresectable hepatocellular carcinoma［J］. Expert Rev Anticancer Ther, 2017, 17(7): 567-576.
［23］Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity ［J］. Int J Cancer, 2011, 129(1): 245-255.
［24］Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial［J］. Lancet, 2017, 389(10064): 56-66.
［25］李槐. 针对"瑞戈非尼用于索拉非尼治疗后进展的肝细胞癌患者（RESORCE）：一项随机、双盲、安慰剂对照Ⅲ期临床试验"导读［J］. 肝癌电子杂志, 2017, 4(1): 3-12.
［26］Finn RS, Merle P, Granito A, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial ［J］. J Hepatol, 2018, 69(2): 353-358.
［27］Baxter MA, Glen H, Evans TR. Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma ［J］. Future Oncol, 2018, 14(20): 2021-2029.
［28］Okamoto K, Ikemori-Kawada M, Jestel A, et al. Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization［J］. ACS Med Chem Lett, 2015, 6(1): 89-94.
［29］Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial ［J］. Lancet, 2018, 391(10126): 1163-1173.
［30］Personeni N, Pressiani T, Rimassa L. Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date ［J］. J Hepatocell Carcinoma, 2019, 6: 31-39.
［31］Kudo M. Lenvatinib in advanced hepatocellular carcinoma［J］. Liver Cancer, 2017, 6(4): 253-263.
［32］Kudo M. Cabozantinib as a second-line agent in advanced hepatocellular carcinoma ［J］. Liver Cancer, 2018, 7: 123-133.
［33］Kelley RK, Verslype C, Cohn AL, et al. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study ［J］. Ann Oncol, 2017, 28(3): 528-534.
［34］Abou-Alfa GK, Tim M, Ann-Lii C, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma［J］. N Engl J Med, 2018, 379(1): 54-63.
［35］Qin S. Apatinib in Chinese patients with advanced hepatocellular carcinoma: A phase II randomized, openlabel trial ［C］. Asco Meeting Abstracts, 2014, 32.
［36］Tian S, Quan H, Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo［J］. Cancer Sci, 2011, 102(7): 1374-1380.
［37］Kong Y, Sun L, Hou Z, et al. Apatinib is effective for treatment of advanced hepatocellular carcinoma ［J］. Oncotarget, 2017, 8(62): 105596-105605.
［38］Yingling JM, Mcmillen WT, Yan L, et al. Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor［J］. Oncotarget, 2018, 9(6): 6659-6677.
［39］Serova M, Annemilai TR, Célia DS, et al. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients ［J］. Oncotarget, 2015, 6(25): 21614-21627.
［40］Ikeda M, Morimoto M, Tajimi M, et al. A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma ［J］. Invest New Drugs, 2019, 37(1): 118-126.
［41］Faivre S, Raymond E, Boucher E, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study ［J］. Lancet Oncol, 2009, 10(8): 794-800.
［42］Llovet JM, Decaens T, Raoul JL, et al. 1398 brivanib versus placebo in patients with advanced hepatocellular carcinoma (hcc) who failed or were intolerant to sorafenib: results from the phase 3 brisk-ps study ［J］. J Clin Oncol, 2013, 31(28): 3509.
［43］De RL, Blanc JF. Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma ［J］. Expert Opin Emerg Drugs, 2017, 22(2): 175-190.
［44］Jordi M, Angel JDLR, Fernando D, et al. Targeting tyrosine kinase receptors in hepatocellular carcinoma ［J］. Curr Cancer Drug Targets, 2013, 13(3): 300-312.
［45］刘琦. mRECIS标准在评估原发性肝癌治疗疗效肿瘤活性的临床价值［D］. 南方医科大学, 2014.
［46］Lencioni R, Montal R, Torres F, et al. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC ［J］. J Hepatol, 2017, 66(6): 1166-1172.
［47］Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma ［J］. Semin Liver Dis, 2010, 30(1): 52-60.

[1]	仲伟, 史淑霞, 秦沁悦, 余果. 临床研究协调员工作能力与工作量的测量工具及合理性评估[J]. 中国临床药理学与治疗学, 2023, 28(8): 937-947.
[2]	王智, 周鑫, 何雪茹, 付裕豪, 荀雪姣, 李颖, 董占军. 哌柏西利治疗乳腺癌的临床研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 205-213.
[3]	吴先闯, 刘瑜新, 牛玉季, 赫锦锦, 乔辉, 张蕾蕾. 肝细胞癌中DCLK1转录调控的机制研究[J]. 中国临床药理学与治疗学, 2023, 28(11): 1241-1246.
[4]	徐俪颖王淑华张高松黄继汉黄小民. 和胃止泻胶囊治疗腹泻患者的临床疗效和模型化评价[J]. 中国临床药理学与治疗学, 2022, 27(1): 47-55.
[5]	叶凯丽, 郑雯, 叶啟发, 杨岚. CDK1参与肝细胞癌的发展机制及其抑制剂应用价值[J]. 中国临床药理学与治疗学, 2021, 26(9): 1086-1094.
[6]	余赛红, 郑晓亮, 蒲依依, 颜冬梅, 王孝举, 于洁. 通过核糖核苷酸还原酶M2逆转肝癌细胞对5-氟尿嘧啶耐药[J]. 中国临床药理学与治疗学, 2021, 26(7): 729-737.
[7]	宋如铮, 彭英, 王广基, 孙建国. 定量蛋白质组学常用研究技术及其在肝源性疾病发病机制中的应用进展[J]. 中国临床药理学与治疗学, 2021, 26(5): 570-578.
[8]	李庆娜, 黄珂, 陆芳, 赵阳, 邱攀博, 王淑阁, 高蕊. 中医药临床研究电子数据管理特点及标准操作规程的制定[J]. 中国临床药理学与治疗学, 2020, 25(5): 550-554.
[9]	郭薇, 谢林利, 曹丽亚, 谢江川, 夏培元, 陈勇川. 重庆市药物临床试验机构现状分析及地区性机构体系构建的思考[J]. 中国临床药理学与治疗学, 2020, 25(10): 1125-1130.
[10]	高敬书, 王宇, 秦慧超, 朱梦一, 吴效科. 特力阿扎维林治疗COVID-19临床研究的“核心数据靶向性”质控策略[J]. 中国临床药理学与治疗学, 2020, 25(10): 1171-1177.
[11]	车津晶. 生物标志物在生物药临床研究中的应用及生物分析策略[J]. 中国临床药理学与治疗学, 2020, 25(1): 22-31.
[12]	杨书才，张莉，刘利平，邓唯杰，周杰，刘慧，张鲍虎，金涛. 缺氧诱导因子2α对肝细胞癌化疗耐药性的影响[J]. 中国临床药理学与治疗学, 2019, 24(6): 630-636.
[13]	蔡民，许浏，沈兰，张杰. 长链非编码RNA FOXN3-AS2在肝癌中的表达及其对肝癌细胞增殖和侵袭的影响[J]. 中国临床药理学与治疗学, 2018, 23(11): 1246-1251.
[14]	肖亮，郑高哲，黄瑜敏. 临床试验基于风险的管理研究进展[J]. 中国临床药理学与治疗学, 2017, 22(8): 955-960.
[15]	江波，杨丹丹，胡殷，阮邹荣. 药物临床试验机构CRC管理模式及管理难点探讨[J]. 中国临床药理学与治疗学, 2016, 21(2): 181-183.